Grace Therapeutics (GRCE) Expected to Announce Quarterly Earnings on Thursday

Grace Therapeutics (NASDAQ:GRCE) is projected to release its Q3 2026 results before the market opens on Thursday, February 12th. Analysts expect Grace Therapeutics to post earnings of ($0.09) per share for the quarter. Parties can check the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 6:00 PM ET.

Grace Therapeutics (NASDAQ:GRCE) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). On average, analysts expect Grace Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Grace Therapeutics Price Performance

Shares of GRCE opened at $3.68 on Thursday. The firm’s 50 day simple moving average is $3.49 and its 200 day simple moving average is $3.24. The company has a market capitalization of $56.93 million, a P/E ratio of -5.94 and a beta of 0.76. Grace Therapeutics has a 1-year low of $1.75 and a 1-year high of $3.94.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Grace Therapeutics to a “hold” rating in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Grace Therapeutics has a consensus rating of “Hold” and a consensus target price of $12.00.

Institutional Trading of Grace Therapeutics

A hedge fund recently bought a new stake in Grace Therapeutics stock. SeaCrest Wealth Management LLC acquired a new stake in shares of Grace Therapeutics, Inc. (NASDAQ:GRCE) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 14,000 shares of the company’s stock, valued at approximately $42,000. SeaCrest Wealth Management LLC owned 0.10% of Grace Therapeutics at the end of the most recent quarter. Institutional investors own 6.08% of the company’s stock.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.